Residency · Residency · Allergy Immunology

Adaptive Immunity - T Cell Development and Function

Introduction

Defining Features of Adaptive Immunity

The adaptive immune system represents a relatively recent evolutionary innovation, emerging approximately 450 million years ago in jawed vertebrates, and possesses several defining characteristics that fundamentally distinguish it from innate immunity. The hallmark of adaptive immunity is antigen specificity, achieved through the generation of an extraordinarily diverse repertoire of somatically rearranged antigen receptors, the T cell receptor (TCR) and B cell receptor (BCR). Each lymphocyte bears a unique receptor with a distinct antigen-binding specificity, and when a lymphocyte encounters its cognate antigen, it undergoes clonal selection and expansion, generating a large population of effector cells bearing identical receptors. This clonal selection mechanism, first articulated by Burnet, ensures that the immune response is focused precisely on the invading pathogen.

Immunologic memory, the ability to mount a faster, stronger, and more effective secondary response upon re-encounter with a previously encountered antigen, is another cardinal feature of adaptive immunity and forms the biological basis of vaccination. Self-tolerance, maintained through both central mechanisms (thymic deletion of self-reactive T cells, bone marrow editing of self-reactive B cells) and peripheral mechanisms (anergy, regulatory T cells, activation-induced cell death), prevents the adaptive immune system from attacking the host's own tissues. A critical distinction from innate immunity is the temporal lag: while innate immune responses are measured in minutes to hours, primary adaptive immune responses require days to weeks to reach full effector capacity, though memory responses are mounted within hours to days.

T Cell Development in the Thymus

Thymic Architecture

The thymus provides the unique microenvironment essential for T cell development and selection. It is organized into two principal compartments with distinct functions. The cortex is densely packed with immature thymocytes and contains cortical thymic epithelial cells (cTECs) and macrophages. The medulla, by contrast, is less densely cellular and contains more mature thymocytes alongside medullary thymic epithelial cells (mTECs), dendritic cells, and the characteristic Hassall's corpuscles, concentrically layered keratinized epithelial structures whose function includes the promotion of TSLP-dependent dendritic cell maturation and thymic regulatory T cell generation. T cell progenitors enter the thymus from the bone marrow via blood vessels at the corticomedullary junction. Thymic involution, a gradual replacement of functional thymic tissue with adipose tissue, begins at puberty and continues throughout life. However, residual thymic tissue persists well into adulthood and maintains some degree of T cell production, as evidenced by the continued detection of T cell receptor excision circles (TRECs) in peripheral blood.

Early T Cell Development

T cell development begins when bone marrow-derived hematopoietic progenitors, which lack expression of CD4, CD8, and the TCR, migrate to and seed the thymus. Upon arrival, Notch1 signaling, induced by interaction with the Notch ligand DLL4 (Delta-like ligand 4) expressed on thymic stromal cells, is essential and sufficient for committing these multipotent progenitors to the T cell lineage while suppressing alternative fates such as B cell or myeloid development.

The earliest intrathymic T cell progenitors are classified as double-negative (DN) cells based on their lack of both CD4 and CD8 expression. The DN compartment is subdivided into four sequential stages defined by the surface markers CD44 and CD25. DN1 cells (CD44+CD25-) represent the thymic seeding progenitors. At the DN2 stage (CD44+CD25+), rearrangement of the TCR beta chain gene locus begins. The DN3 stage (CD44-CD25+) represents a critical developmental checkpoint known as beta-selection, where productive rearrangement of the TCR beta chain is tested. At the DN4 stage (CD44-CD25-), cells that have successfully passed beta-selection undergo rapid proliferation.

Beta-selection is a pivotal quality control checkpoint. A successfully rearranged TCR beta chain pairs with the invariant pre-T alpha (pTalpha) chain to form the pre-TCR complex. Signaling through the pre-TCR initiates a cascade of events: it provides essential survival signals that rescue the cell from apoptosis, drives rapid proliferative expansion, establishes allelic exclusion of the second TCR beta locus (ensuring that each T cell expresses only one beta chain), and promotes progression to the double-positive stage.

TCR Gene Rearrangement

The generation of TCR diversity relies on V(D)J recombination, a process of somatic DNA rearrangement mediated by the lymphoid-specific recombinases RAG1 and RAG2 (recombination-activating genes 1 and 2). The TCR beta and TCR delta loci contain variable (V), diversity (D), and joining (J) gene segments, while the TCR alpha and TCR gamma loci contain only V and J segments, lacking D segments. During rearrangement, one V, one D (if present), and one J segment are selected and joined, with the intervening DNA excised as circular byproducts (signal joint TRECs).

Additional diversity is generated at the junctions between gene segments through two mechanisms: P-nucleotides (palindromic nucleotides generated by asymmetric opening of the hairpin coding ends) and N-nucleotides (non-templated nucleotides added by the enzyme terminal deoxynucleotidyl transferase, TdT). These junctional modifications are concentrated at the CDR3 region of the TCR, the region that makes the most critical contacts with peptide-MHC complexes. The theoretical diversity of the TCR repertoire exceeds 10^15 unique receptors, vastly exceeding the number of T cells in any individual and ensuring that virtually any foreign peptide can be recognized.

Deficiency of RAG1 or RAG2 abolishes V(D)J recombination entirely, resulting in T-B-NK+ SCID (severe combined immunodeficiency with absent T and B cells but preserved NK cells, which do not require RAG-mediated receptor rearrangement). Hypomorphic RAG mutations, which retain partial recombinase activity, can cause Omenn syndrome, characterized by oligoclonal T cell expansion, erythroderma, eosinophilia, and elevated IgE.

<image>A detailed diagram of T cell development in the thymus showing the cortex-to-medulla journey. Left side shows bone marrow progenitor entering at corticomedullary junction. Sequential stages depicted: DN1 through DN4 in the subcapsular/cortical region with TCR beta rearrangement and beta-selection checkpoint highlighted. Then transition to CD4+CD8+ double-positive (DP) stage with TCR alpha rearrangement. Positive selection by cTECs shown with MHC-I and MHC-II interactions. Negative selection at the corticomedullary junction and medulla with mTECs and DCs. Final output of mature CD4+ or CD8+ single-positive T cells exiting the thymus. Include molecular markers (CD44, CD25, CD4, CD8) at each stage.</image>

Double-Positive (DP) Stage and Selection

Following beta-selection, thymocytes upregulate both CD4 and CD8 to become double-positive (DP) cells, which constitute the vast majority of thymocytes. At this stage, rearrangement of the TCR alpha chain locus occurs. Importantly, the TCR delta locus is physically embedded within the TCR alpha locus, and rearrangement of TCR alpha deletes the TCR delta locus, ensuring that alpha-beta and gamma-delta lineage commitment are mutually exclusive. DP thymocytes express low levels of the completed alpha-beta TCR and are now subjected to the two complementary selection processes that shape the mature T cell repertoire.

Positive Selection (Cortex)

Positive selection takes place in the thymic cortex and is mediated by cortical thymic epithelial cells (cTECs), which present a unique repertoire of self-peptides on MHC class I and MHC class II molecules. cTECs employ a specialized proteasome (the thymoproteasome, containing the beta5t subunit) and unique cathepsins (cathepsin L rather than cathepsin S) to generate peptides that are distinct from those presented by other antigen-presenting cells, which may be important for selecting a T cell repertoire capable of recognizing diverse peptide-MHC complexes in the periphery.

Only thymocytes whose TCR binds self-peptide-MHC complexes with intermediate affinity receive survival signals and proceed in development. Those TCRs that fail to bind any self-peptide-MHC complex at all die by neglect, a fate that befalls approximately 90 percent of all DP thymocytes. Positive selection also establishes MHC restriction: thymocytes that interact with MHC class II commit to the CD4 lineage, while those that interact with MHC class I commit to the CD8 lineage. This lineage commitment is governed by the transcription factors ThPOK (which drives CD4 lineage commitment by repressing CD8 genes) and Runx3 (which drives CD8 lineage commitment).

Negative Selection (Cortex and Medulla)

Negative selection eliminates thymocytes bearing TCRs with excessively high affinity for self-peptide-MHC complexes, thereby purging potentially autoreactive clones from the repertoire. This process occurs at both the corticomedullary junction and within the medulla. The medulla is the principal site of negative selection against tissue-restricted antigens, a process critically dependent on the transcription factor AIRE (autoimmune regulator), which is expressed in medullary thymic epithelial cells and drives the ectopic expression of a wide array of tissue-restricted self-antigens. These include proteins normally confined to specific organs, such as insulin (pancreatic beta cells) and thyroglobulin (thyroid follicular cells). By presenting these tissue-restricted antigens in the thymus, AIRE ensures that T cells reactive to peripheral self-antigens are deleted before they ever reach the circulation.

Deficiency of AIRE causes APS-1/APECED (autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy), a syndrome classically defined by the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Patients with APECED also characteristically produce autoantibodies against cytokines, particularly anti-IL-17 and anti-IL-22 (which explain the susceptibility to candidiasis by neutralizing the key antifungal cytokines) and anti-IFN-omega (a diagnostically useful serologic marker). A second transcription factor, Fezf2, has been identified as an additional regulator of tissue-restricted antigen expression in mTECs, complementing the function of AIRE.

An alternative fate for high-affinity self-reactive thymocytes is diversion to the regulatory T cell lineage. Rather than undergoing apoptosis, some thymocytes with relatively high self-reactivity are induced to upregulate FoxP3 and differentiate into CD4+CD25+FoxP3+ natural regulatory T cells (nTregs), which will emigrate to the periphery and function to suppress autoreactive immune responses.

Mature T Cell Subsets

CD4+ T Helper Subsets

Upon activation in the periphery, naive CD4+ T cells differentiate into functionally distinct effector subsets, each characterized by a master transcription factor, a signature cytokine profile, and a specialized role in host defense.

Th1 cells are defined by the master transcription factor T-bet and produce IFN-gamma, TNF-alpha, and IL-2. They are the principal effectors against intracellular pathogens, including mycobacteria, Listeria, and certain viruses. Th1 differentiation is driven by IL-12 (produced by activated macrophages and dendritic cells) and IFN-gamma, signaling through STAT4.

Th2 cells are defined by the master transcription factor GATA-3 and produce IL-4, IL-5, and IL-13. They orchestrate defense against helminths and, when dysregulated, drive allergic inflammation through IgE class switching (IL-4), eosinophil recruitment and activation (IL-5), and mucus hypersecretion with airway hyperresponsiveness (IL-13). Th2 differentiation is driven by IL-4 signaling through STAT6.

Th17 cells are defined by the master transcription factor RORgammat and produce IL-17A, IL-17F, and IL-22. They are essential for mucosal defense against extracellular bacteria and fungi, particularly at barrier surfaces. In mice, Th17 differentiation is driven by TGF-beta plus IL-6, while in humans, IL-1beta plus IL-23 appear to be the dominant polarizing cytokines, signaling through STAT3. The clinical importance of STAT3 in this pathway is demonstrated by the contrasting phenotypes of STAT3 gain-of-function mutations (multisystem autoimmunity driven by excessive Th17 and other effector responses) and STAT3 loss-of-function mutations, which cause autosomal dominant hyper-IgE syndrome (AD-HIES/Job syndrome) with recurrent staphylococcal and candidal infections attributable to impaired Th17 immunity.

T follicular helper (Tfh) cells are defined by the master transcription factor Bcl-6 and produce IL-21 and IL-4. They express the chemokine receptor CXCR5, which directs their migration into B cell follicles, along with the co-stimulatory molecule ICOS and the co-inhibitory receptor PD-1. Tfh cells are essential for germinal center formation and the provision of help to B cells for high-affinity antibody production.

Additional subsets include Th9 cells (producing IL-9, driven by TGF-beta plus IL-4, with roles in helminth immunity and allergic inflammation) and Th22 cells (producing IL-22, important for skin barrier defense and epithelial repair).

<image>A comprehensive table-style illustration of CD4+ T helper cell subsets arranged in a circular or radial pattern. Center shows a naive CD4+ T cell. Radiating outward, each subset (Th1, Th2, Th17, Tfh, Treg, Th9, Th22) is shown with: (1) the polarizing cytokines that drive differentiation (arrows from naive cell), (2) the master transcription factor (shown inside the cell nucleus), (3) key surface markers, (4) signature effector cytokines (arrows pointing outward), and (5) primary function/target pathogen in a text box. Use distinct colors for each subset. Include cross-regulation arrows showing Th1 inhibiting Th2 (via IFN-gamma) and Th2 inhibiting Th1 (via IL-4).</image>

CD8+ Cytotoxic T Lymphocytes (CTLs)

CD8+ cytotoxic T lymphocytes recognize intracellular antigens presented on MHC class I molecules, which are expressed on virtually all nucleated cells. This endows CTLs with the ability to survey any cell in the body for evidence of intracellular infection or malignant transformation. CTLs employ two principal killing mechanisms. The perforin/granzyme pathway involves the directed exocytosis of cytolytic granules containing perforin, which polymerizes to form transmembrane pores in the target cell membrane, and granzymes (particularly granzyme B), which enter through these pores and activate the caspase cascade, inducing apoptosis. The Fas/FasL pathway involves the expression of Fas ligand (FasL, CD95L) on the CTL surface, which engages Fas (CD95) on the target cell, triggering the extrinsic apoptotic cascade. Mutations in Fas cause autoimmune lymphoproliferative syndrome (ALPS) type Ia, characterized by defective lymphocyte apoptosis and chronic lymphoproliferation.

CD8+ T cell memory is organized into distinct subsets: central memory T cells (Tcm), which express the lymph node homing markers CCR7 and CD62L and reside in secondary lymphoid organs, and effector memory T cells (Tem), which lack these markers and circulate through peripheral tissues, providing rapid effector function at sites of infection.

Regulatory T Cells (Tregs)

Regulatory T cells are the master regulators of immune homeostasis and self-tolerance. Natural Tregs (nTregs) are generated in the thymus from thymocytes with relatively high self-reactivity and are characterized by the phenotype CD4+CD25hiCD127lowFoxP3+. Induced Tregs (iTregs) are generated in the periphery from naive CD4+ T cells under the influence of TGF-beta and IL-2.

Tregs employ multiple mechanisms of suppression. They secrete the immunosuppressive cytokines IL-10 and TGF-beta, which dampen effector T cell function and promote immune tolerance. They express CTLA-4, which competes with the co-stimulatory receptor CD28 for binding to B7 ligands on antigen-presenting cells with 10 to 20-fold higher affinity, and which can physically remove B7 molecules from the APC surface through trans-endocytosis, thereby depriving effector T cells of co-stimulation. Tregs also express high levels of CD25 (the IL-2 receptor alpha chain), which allows them to consume IL-2 from the local microenvironment, depriving effector T cells of this critical growth and survival factor. Additionally, Tregs can directly kill effector cells through granzyme/perforin-mediated cytolysis.

Mutations in FoxP3 cause IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked), one of the most dramatic demonstrations of the essential role of Tregs in immune tolerance. IPEX presents in male infants with severe autoimmune enteropathy (intractable watery diarrhea and failure to thrive), neonatal-onset type 1 diabetes mellitus, and eczematous dermatitis. IgE levels are typically markedly elevated. Without treatment, IPEX is fatal; hematopoietic stem cell transplantation is curative, and sirolimus can provide supportive immunosuppression.

Gamma-Delta T Cells

Gamma-delta T cells constitute a minor population of circulating T cells (1 to 5 percent) but are markedly enriched in epithelial tissues, particularly the skin, gut mucosa, and lung. Unlike conventional alpha-beta T cells, gamma-delta T cells do not require classical MHC-restricted antigen presentation and can recognize antigens directly, including phosphoantigens (such as isopentenyl pyrophosphate) and stress-induced ligands. The predominant subset in human peripheral blood is the Vgamma9Vdelta2 population, which responds to microbial and host cell-derived phosphoantigens. Gamma-delta T cells contribute to infection control, tumor surveillance, and tissue repair, and they bridge innate and adaptive immunity through their rapid effector responses and tissue residency.

T Cell Activation and Co-stimulation

Three-Signal Model

T cell activation in the periphery follows a well-established three-signal model. Signal 1, the specificity signal, is provided by engagement of the TCR with its cognate peptide-MHC complex on the surface of an antigen-presenting cell. This interaction alone is insufficient for productive activation. Signal 2, the co-stimulatory signal, is provided by the interaction of CD28 on the T cell with B7-1 (CD80) or B7-2 (CD86) on the APC. In the absence of co-stimulation, TCR engagement leads to anergy, a state of functional unresponsiveness in which the T cell is alive but incapable of mounting an effector response upon subsequent stimulation. Signal 3 is provided by the cytokine milieu established by the APC and the local inflammatory environment, which directs the differentiation of the activated T cell into a specific effector subset (for example, IL-12 for Th1, IL-4 for Th2, IL-6 plus TGF-beta for Th17).

Co-stimulatory and Co-inhibitory Molecules

Beyond CD28, T cells express a diverse array of co-stimulatory and co-inhibitory receptors that fine-tune the immune response. Co-stimulatory molecules include ICOS (important for Tfh cell function), OX40 (CD134, promoting T cell survival and memory), 4-1BB (CD137, enhancing effector function), and CD40L (which provides reciprocal activation signals to APCs). Co-inhibitory molecules, collectively termed immune checkpoints, include CTLA-4, PD-1, LAG-3, TIM-3, and TIGIT.

CTLA-4 is constitutively expressed on regulatory T cells and induced on activated effector T cells. It binds B7 ligands with 10 to 20-fold higher affinity than CD28, functioning as a molecular brake on T cell activation. Haploinsufficiency of CTLA-4, caused by heterozygous loss-of-function mutations, results in an autosomal dominant immune dysregulation syndrome characterized by autoimmune cytopenias, lymphocytic organ infiltration (lungs, brain, gut), hypogammaglobulinemia, and lymphoproliferation. This condition is treatable with abatacept (CTLA-4-Ig), a recombinant fusion protein that supplements the deficient CTLA-4 function.

PD-1 and its ligands PD-L1 and PD-L2 function to limit T cell effector function within peripheral tissues, preventing immune-mediated tissue damage. Tumor cells frequently exploit the PD-1/PD-L1 axis to evade immune destruction by upregulating PD-L1 expression. Checkpoint inhibitor immunotherapy, including pembrolizumab and nivolumab (anti-PD-1) and atezolizumab (anti-PD-L1), releases this brake and restores anti-tumor T cell immunity. However, by releasing immune checkpoints, these therapies can cause immune-related adverse events (irAEs) that mimic autoimmune diseases and can affect virtually any organ system.

TCR Signaling Cascade

The molecular events downstream of TCR engagement represent a highly organized signaling cascade. TCR engagement triggers the activation of Lck, a Src family kinase associated with the cytoplasmic tails of the CD4 and CD8 co-receptors. Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 zeta chains of the TCR complex. The phosphorylated ITAMs recruit the tyrosine kinase ZAP-70, which in turn phosphorylates the scaffold proteins LAT (linker for activation of T cells) and SLP-76, forming a signalosome that nucleates three major downstream signaling pathways.

The PLCgamma1 pathway cleaves PIP2 into IP3 (which triggers calcium release from the ER, leading to calcineurin activation, NFAT dephosphorylation, and NFAT nuclear translocation) and DAG (which activates PKCtheta, leading to NF-kB nuclear translocation). The Ras/MAPK pathway activates the Ras-Raf-MEK-ERK cascade, leading to AP-1 activation. The PI3K/Akt pathway promotes cell survival and metabolic reprogramming. Co-stimulatory signaling from CD28 feeds into the PI3K pathway, augmenting T cell activation, survival, and proliferation.

These signaling pathways are also the targets of several clinically important immunosuppressive drugs. Cyclosporine and tacrolimus inhibit calcineurin, preventing NFAT dephosphorylation and blocking IL-2 transcription. Rapamycin (sirolimus) inhibits mTOR downstream of PI3K/Akt, blocking T cell proliferation and promoting regulatory T cell generation.

ZAP-70 deficiency results in a distinctive immunodeficiency phenotype in which CD4+ T cells are present but non-functional (unable to signal through the TCR), while CD8+ T cells are absent (due to failed positive selection on MHC class I, which requires ZAP-70 signaling).

<image>A signaling cascade diagram showing the TCR signaling pathway from antigen recognition to transcription factor activation. The illustration begins with the TCR-CD3 complex engaging peptide-MHC, showing Lck phosphorylating CD3 ITAMs, ZAP-70 recruitment, and activation of LAT/SLP-76 signalosome. Three downstream branches are depicted: (1) PLCgamma1 cleaving PIP2 into IP3 (calcium release, calcineurin activation, NFAT dephosphorylation and nuclear translocation) and DAG (PKCtheta activation, NF-kB nuclear translocation), (2) Ras/Raf/MEK/ERK pathway leading to AP-1, and (3) PI3K/Akt pathway. Co-stimulatory signal from CD28 feeding into PI3K is shown. Drug targets are highlighted: cyclosporine/tacrolimus blocking calcineurin, and rapamycin (sirolimus) blocking mTOR.</image>

Key Clinical Pearls

• RAG1/RAG2 deficiency causes T-B-NK+ SCID; hypomorphic mutations can cause Omenn syndrome with oligoclonal T cell expansion
• AIRE deficiency (APS-1/APECED) presents with the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency
• FoxP3 deficiency (IPEX) is X-linked and presents with severe autoimmune enteropathy, T1DM, and eczema in male infants
• CTLA-4 haploinsufficiency is an autosomal dominant immune dysregulation syndrome treatable with abatacept
• The Th1/Th2 paradigm in allergic disease: Th2 skewing (IL-4, IL-5, IL-13) drives IgE production, eosinophilia, and mucus hypersecretion
• Checkpoint inhibitor-induced immune-related adverse events reflect loss of peripheral tolerance and can affect any organ system
• ZAP-70 deficiency causes a selective CD8 lymphopenia with non-functional CD4 T cells

References

1. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol. 2002;2(5):309-322.
2. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445-489.
3. Anderson MS, et al. Projection of an immunological self shadow within the thymus by the AIRE protein. Science. 2002;298(5597):1395-1401.
4. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
5. Tangye SG, et al. Human inborn errors of immunity: 2022 update on the classification from the IUIS Expert Committee. J Clin Immunol. 2022;42(7):1473-1507.

Read this lecture as Markdown